Cambrex acquires EU’s leading stabilizing bearing company Q1 Scientific | News

EAST RUTHERFORD, NJ, June 2, 2022 / PRNewswire / – Cambrex, a leading global contract development and manufacturing (CDMO) company that provides drug ingredients, drug products and analytical services throughout the drug lifecycle, today announced that it has acquired Q1 Scientific – a leading supplier of controlled storage for the environment the stability of cGMP services for the pharmaceutical, medical devices and life sciences industries strategically located in WaterfordIreland.

“Testing storage and stability is a key part of drug development and commercialization of new therapies. Q1 Scientific adds world-class capabilities to our ever-expanding portfolio of outsourced pharmaceutical services. ” Tom Loewaldgeneral manager by Cambrex. “This acquisition is a natural extension of our current offer, which will expand and strengthen our knowledge in this important area and our presence on the European market.

Q1 Scientific’s state-of-the-art cGMP facility has been validated by ICH to meet the specific storage needs of each pharmaceutical project, with options from -80C to + 50C, with a full range of humidity controls. The 20,000 square foot facility in Waterford has almost 40 stability chambers, freezers and stability units, and chest freezers for biological therapies. The company also offers sample management and transportation services.

“We are delighted to be joining Cambrex as we continue to provide our existing customers with leading stability storage services,” he said. Stephen Delaney, CEO of Q1 Scientific. “With Cambrex’s scientific expertise and scale, we will be able to accelerate our growth and offer an integrated suite of analytical services that offers our clients a wide range of market-leading solutions.”

Cambrex offers a variety of storage and testing options with entry and exit chambers that meet ICH Q1A requirements. The acquisition will expand Cambrex’s capabilities in the European market.

As pharmaceutical and biopharmaceutical companies continue to look for outsourcing options for non-essential functions to reduce their footprint, Q1 Scientific’s Stable Storage Services coupled with Cambrex’s industry-leading portfolio of analytical services provide specialized capabilities with high value to the industry.

Information about Cambrex

Cambrex is a leading global contract manufacturing and manufacturing organization (CDMO) that provides drug ingredients, drug products and analytical services throughout the drug lifecycle. Cambrex has over 40 years of experience and employs a growing team of over 2,200 professionals serving clients worldwide from North America and Europe. The company is a reliable partner in the development and production of active ingredients and dosage forms for branded and generic products.

Cambrex offers a range of specialized drug technologies and capabilities, including biocatalysis, continuous flow, controlled substances, solid state discovery, material characterization, and high-potency drugs. In addition, Cambrex has the ability to handle conventional dosage forms including oral solid, semi-solid and liquid dosage forms, and has experience in making specialty dosage forms such as e.g. B. Modified release tablets, fixed dose combination products, pediatric products. , bilayer tablets, stick packs, topical products, controlled substances, and sterile and non-sterile ointments.

OI academic quarter

Q1 Scientific was founded in 2013 by Louise Grubb in Waterford, Ireland, providing environmentally controlled stability storage services to the pharmaceutical, medical devices and life sciences industries from its 20,000 square meter cGMP facility. As the first Irish-based company in the industry, Q1 Scientific is revolutionizing the way pharmaceutical companies store their products, helping new drugs get to market faster, and helping companies reduce construction costs and … Save on monitoring their own storage chambers.

Visit or for more information


Jennifer Therrien




Leave a Comment